Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Brian Wainger
Massachusetts General Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
QurAlis
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Wainger is a paid consultant for QurAlis. He owns equity in the privately held company and receives cash compensation for serving on the SAB for the company. QurAlis is developing precision medicine therapies for the treatment of ALS. The company is currently developing therapies for three sub-forms of ALS: Immune System Malfunction, C9orf72 Repeat Expansion Toxicity, and Altered Motor System Excitability. This research grant is focused on ALS and the company could therefore have an interest in the results of the research. The Partners Committee on Outside Activities review panel evaluated Dr. Wainger’s financial interest in connection with the research and determined that the financial interest could directly and significantly affect the design, conduct, or reporting of the research.
A Human Stem Cell-Derived Neuromuscular Junction Model for Amyotrophic Lateral Sclerosis
Project�Narrative:� The�proposed�research�will�develop�a�model�using�human�induced�pluripotent�stem�cells�of�the� neuromuscular�junction,�the�site�of�initial�clinical�and�pathological�features�of�amyotrophic�lateral� sclerosis,�commonly�known�as�Lou�Gehrig?s�disease.�The�proposed�research�will�combine�innovative� stem�cell�biology,�electrophysiology�and�genomics�and�lead�to�molecular�targets�and�treatment� strategies�for�this�devastating�condition.� �
Filed on May 01, 2018.
Tell us what you know about Brian Wainger's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Brian Wainger filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Brian Wainger | Massachusetts General Hospital | Conflict of Interest | QurAlis | $5,000 - $9,999 |
| Brian Wainger | Massachusetts General Hospital | Conflict of Interest | QurAlis | $5,000 - $9,999 |
| Brian Wainger | Massachusetts General Hospital | Conflict of Interest | QurAlis | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.